News & Events
10 May 2012 DIABETES AT THE COALFACE
Following on from the success of last year’s event, I am delighted to announce that the Welsh Conference of the Primary Care Diabetes Society will be held again in Cardiff on 10 May this year.
Hosted by Dr Pam Brown and Dr David Millar-Jones, Welsh representatives of the PCDS, this event will provide you with continuing professional development, an opportunity to learn from some leading diabetes experts in Wales and a chance to network with your peers and discuss the key issues that affect you in day-to-day clinical practice.
Through lectures and interactive masterclasses this event will provide practical guidance to healthcare professionals on issues that impact everyday diabetes practice in Wales. Entitled “Diabetes at the Coalface – Management strategies for type 2 diabetes in Wales”, this year’s event covers topics including:
- Diagnosing diabetes and how to screen for it
- Diabetes therapies: out with the old and in with the new?
- Obesity: a Welsh perspective
New resources due to be launched before this year’s conference will also provide you with extended CPD opportunities, such as online post-event education and tools to help you put in place action plans within your practice.
This cost to attend this event this year has been reduced to £75 for PCDS members* and £95 for non-members. However, by booking before 29 February, you can take advantage of the of the early-bird price of £60 and £75 respectively.
For more information or to book on this exciting conference please click here or call the events team on: 0207 627 1510.
We hope that you will be able to join us at this important and influential event.
Both diets achieved substantial improvements for several clinical glycemic control and CVD risk markers. These improvements and reductions in GV and antiglycemic medication requirements were greatest with the LC compared with HC (Diabetes Care)
A new study is planned for the Diamyd® diabetes vaccine that will comprise 80 children with high risk of presenting with type 1 diabetes. The aim is to test whether the diabetes vaccine can prevent or delay the onset in the children (Diamyd)
Latent Autoimmune Diabetes in Adults With Low-Titer GAD Antibodies: Similar Disease Progression With Type 2 Diabetes: A Nationwide, Multicenter Prospective Study (LADA China Study 3)
In selected LADA patients, initial GADA titers identified subjects with different degrees of persistent autoimmunity and disease progression. LADA patients with a low GADA titer had metabolic phenotypes and loss of ß-cell function similar to type 2 diabetic patients (Diabetes Care)
Benefits of Chinese medicine among patients with diabetic foot: an expert review from clinical studies
It is becoming increasingly important for integrated CM and biomedicine therapy to treat diabetes-related vascular complications. The opportunities for effective CM interventions are significant, and more solid evidence is warranted to show the efficacy of CM in the treatment of diabetic foot ulcers in the near future (Current Vascular Pharmacology)
All 10 evaluated models had a comparable and moderate discriminative ability. The recalibrated, but not the original, prediction models provided accurate risk estimates. These models can assist clinicians in identifying type 2 diabetes patients who are at low or high risk of developing CVD (Heart)